Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk appoints new senior principal clinical scientist

Stephen Gough joins the Danish diabetes giant
Stephen Gough Novo Nordisk

Novo Nordisk has appointed Stephen Gough as senior principal clinical scientist. 

Gough will be responsible for providing clinical guidance on the development of new molecules and drugs from early stage through to phase III and beyond for obesity and diabetes.

He joins from the Oxford Centre for Diabetes Endocrinology and Metabolism, where he worked with research groups focusing on autoimmunity.

He said: “I am excited to join a company with over 90 years of dedication to finding better treatments for diabetes. 

“I look forward to working with the exceptional scientific team at Novo Nordisk to help translate research into meaningful therapies that makes a difference for patients.”

Alan Moses, CMO of Novo Nordisk, added: “With [Gough's] key clinical expertise, his experience as a researcher focused on patient issues, and his compassion for patients with diabetes, Professor Gough will have a vital role in working toward Novo Nordisk's ambition of changing diabetes.”

1st October 2015

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics